Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced…(HFHS 21-01) | Phase 2 | withdrawn | Feb 15, 2021 | Shirish Gadgeel | Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt… | COVID-19 / pandemic |
| NCT02932345 | Gefitinib Long-term Survivor Study | — | terminated | Oct 13, 2016 | AstraZeneca | Due to strategic decision, AZ has applied to terminate study at all participating sites and has… | Sponsor / business decision |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small…(CheckMate 9TN) | Phase 2 | withdrawn | Dec 10, 2018 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell… | Phase 2 | withdrawn | Jan 25, 2016 | GU Research Network, LLC | not stated | Not stated |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage… | Phase 2 | withdrawn | Aug 20, 2019 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1… | Phase 2 | withdrawn | Jul 14, 2020 | Shirish M Gadgeel | Lack of Accrual | Enrollment / accrual |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in… | Phase 2 | terminated | Dec 23, 2014 | Novartis Pharmaceuticals | Sponsor decision due to low patient recruitment caused by the change in the treatment landscape of… | Enrollment / accrual |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With… | Phase 1 / Phase 2 | terminated | Jul 12, 2021 | Shandong Cancer Hospital and Institute | High incidence of severe radiation pneumonia | Other (stated, no rule matched) |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04186988 | [18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer… | Early Phase 1 | withdrawn | Dec 5, 2019 | University of California, Davis | Unable to recruit to study. | Enrollment / accrual |
| NCT03988192 | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy…(Immuno-VOC) | N/A | terminated | Jun 17, 2019 | Hopital Foch | Evolution of the treatment procedures so that their is no more benefits for patients | Other (stated, no rule matched) |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor… | Phase 1 | terminated | Aug 21, 2017 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Feb 17, 2021 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non…(SOLUTION) | Phase 2 | withdrawn | Oct 24, 2017 | European Organisation for Research and Treatment of Cancer - EORTC | Interest withdrawn | Other (stated, no rule matched) |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With… | Phase 1 / Phase 2 | terminated | Nov 15, 2016 | Fox Chase Cancer Center | Study terminated prematurely due to funding/support being withdrawn by grantor | Funding |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 6, 2006 | Cyclacel Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung… | Phase 2 | terminated | Apr 22, 2009 | Cyclacel Pharmaceuticals, Inc. | Limitation in financial resources. | Funding |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | Phase 1 | terminated | Jun 18, 2019 | Shanghai Kechow Pharma, Inc. | drug development strategy adjustment | Sponsor / business decision |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or… | Phase 2 | terminated | Aug 17, 2009 | SCRI Development Innovations, LLC | Study was terminated due to slow accrual | Enrollment / accrual |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | Phase 1 / Phase 2 | terminated | Nov 15, 2019 | Eli Lilly and Company | The study was terminated due to an unexpected toxicity finding. | Safety / toxicity |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT03231475 | Phase I Study of SPH1188-11 in NSCLC(SPH1188-11) | Phase 1 | withdrawn | Jul 27, 2017 | Shanghai Pharmaceuticals Holding Co., Ltd | Board decision | Other (stated, no rule matched) |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT03998189 | Metabolic and Microbial Profiling of Lung Cancer | N/A | terminated | Jun 26, 2019 | Wake Forest University Health Sciences | Study deemed no longer feasible | Other (stated, no rule matched) |
| NCT05007769 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in…(RAN) | Phase 2 | withdrawn | Aug 16, 2021 | Washington University School of Medicine | Lost funding | Funding |
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV… | Phase 2 | withdrawn | Feb 10, 2020 | Emory University | Due to accrual issues | Enrollment / accrual |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With… | Phase 2 | terminated | Dec 4, 2012 | Spectrum Pharmaceuticals, Inc | The study did not meet efficacy end point and did not enroll patients in the randomized phase. | Efficacy / futility |
| NCT01799135 | Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) | N/A | terminated | Feb 26, 2013 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin…(SHERLOC) | Phase 2 | terminated | Mar 12, 2015 | Elevation Oncology | Based on the preliminary results seen during interim analysis, which were confirmed in the final… | Efficacy / futility |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | Phase 1 | terminated | Feb 2, 2011 | Daiichi Sankyo | The trial was terminated as per Sponsor decision. | Sponsor / business decision |
| NCT03624907 | Daily vs. Non-Daily SBRT for NSCLC | N/A | terminated | Aug 10, 2018 | University of Florida | Slow accrual | Enrollment / accrual |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid… | Phase 1 / Phase 2 | terminated | Apr 27, 2017 | Dana-Farber Cancer Institute | Study closed due to slow accrual and lack of efficacy. | Efficacy / futility |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Apr 3, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT04160559 | Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung… | N/A | withdrawn | Nov 13, 2019 | Xinqiao Hospital of Chongqing | There are no suitable participants | Other (stated, no rule matched) |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | Phase 1 | terminated | Jan 2, 2018 | Ascentage Pharma Group Inc. | The company adjusts strategy. | Sponsor / business decision |
| NCT03431415 | Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b)…(RAXSIA) | N/A | withdrawn | Feb 13, 2018 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Accrual issues | Enrollment / accrual |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2020 | NextCure, Inc. | Upon reviewing current available combo studies, the sponsor decided to prioritize different combo… | Sponsor / business decision |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer… | N/A | withdrawn | Sep 11, 2019 | City of Hope Medical Center | Funding issue | Funding |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line…(MERU) | Phase 3 | terminated | Jan 26, 2017 | AbbVie | Independent Data Monitoring Committee recommendation | Other (stated, no rule matched) |
| NCT03245177 | Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung…(PARIS) | Phase 1 | withdrawn | Aug 10, 2017 | Prof Corinne Faivre-Finn | Funding withdrawn. | Funding |
| NCT03200600 | Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | Phase 4 | terminated | Jun 27, 2017 | Peking University First Hospital | Protocol violation occurred frequently during the postoperative period. | Other (stated, no rule matched) |
| NCT01108666 | Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage… | Phase 2 | terminated | Apr 22, 2010 | Abramson Cancer Center at Penn Medicine | Insufficient accrual | Enrollment / accrual |
| NCT04289259 | Tumor Mutational Burden in Lung Cancer Patients(MUBULUC) | — | terminated | Feb 28, 2020 | Assistance Publique - Hôpitaux de Paris | The funder stopped to fund this study. | Funding |
| NCT04611776 | A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy,…(CATHAYA) | Phase 2 | withdrawn | Nov 2, 2020 | Hoffmann-La Roche | The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant… | Enrollment / accrual |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | Phase 1 / Phase 2 | terminated | Jan 29, 2015 | Pfizer | The study was ended for strategic reasons and changes in the external environment. The safety… | Safety / toxicity |
| NCT02768558 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced… | Phase 3 | terminated | May 11, 2016 | RTOG Foundation, Inc. | Another treatment found efficacious | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 29, 2022source: clinicaltrials